Literature DB >> 16940759

Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism.

Sheila M Fleming1, Marie-Françoise Chesselet.   

Abstract

Prior to the discovery of genes associated with familial forms of Parkinson's disease, animal models of Parkinson's disease mainly consisted of toxin models based exclusively on the degeneration of nigrostriatal dopamine neurons. These traditional models have provided valuable insight into symptomatic treatments for Parkinson's disease; however, they lack the broad extra-nigral pathology and the progression that is observed in the disease. The novel genetic mouse models recently generated are advantageous because they have mutations that are known to cause familial Parkinson's disease and thus they have good construct validity. To maximize the utility of these models, a thoughtful phenotypical characterization is important. Our laboratory has assembled a battery of behavioral tests to assess sensorimotor function in genetic mouse models of Parkinsonism. This review discusses the sensitivity of these tests in different genetic mice in addition to their behavioral response to dopamine agonists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940759     DOI: 10.1097/00008877-200609000-00004

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  25 in total

Review 1.  Preservation of function in Parkinson's disease: what's learning got to do with it?

Authors:  Jeff A Beeler
Journal:  Brain Res       Date:  2011-09-29       Impact factor: 3.252

Review 2.  High throughput screening for neurodegeneration and complex disease phenotypes.

Authors:  Hemant Varma; Donald C Lo; Brent R Stockwell
Journal:  Comb Chem High Throughput Screen       Date:  2008-03       Impact factor: 1.339

3.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

4.  The organization of the forelimb representation of the C57BL/6 mouse motor cortex as defined by intracortical microstimulation and cytoarchitecture.

Authors:  Kelly A Tennant; Deanna L Adkins; Nicole A Donlan; Aaron L Asay; Nagheme Thomas; Jeffrey A Kleim; Theresa A Jones
Journal:  Cereb Cortex       Date:  2010-08-25       Impact factor: 5.357

5.  Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia.

Authors:  Marta Ruiz; Georgina Perez-Garcia; Maitane Ortiz-Virumbrales; Aurelie Méneret; Andrika Morant; Jessica Kottwitz; Tania Fuchs; Justine Bonet; Pedro Gonzalez-Alegre; Patrick R Hof; Laurie J Ozelius; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2015-09-16       Impact factor: 6.150

6.  Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

Authors:  H L Melrose; J C Dächsel; B Behrouz; S J Lincoln; M Yue; K M Hinkle; C B Kent; E Korvatska; J P Taylor; L Witten; Y-Q Liang; J E Beevers; M Boules; B N Dugger; V A Serna; A Gaukhman; X Yu; M Castanedes-Casey; A T Braithwaite; S Ogholikhan; N Yu; D Bass; G Tyndall; G D Schellenberg; D W Dickson; C Janus; M J Farrer
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

7.  Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.

Authors:  Meghan R Hennis; Marian A Marvin; Charles M Taylor; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2013-09-26       Impact factor: 5.996

8.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Authors:  Jason R Cannon; Kindiya D Geghman; Victor Tapias; Thomas Sew; Michelle K Dail; Chenjian Li; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2012-11-12       Impact factor: 5.330

9.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

10.  Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.

Authors:  Xiao-Hong Lu; Sheila M Fleming; Bernhard Meurers; Larry C Ackerson; Farzad Mortazavi; Victor Lo; Daniela Hernandez; David Sulzer; George R Jackson; Nigel T Maidment; Marie-Francoise Chesselet; X William Yang
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.